1. Breast Cancer Drug Avastin Faces FDA Panel
For the second time in two years, a panel will go before the FDA's Center for Drug Evaluation and Research (CDER) to fight for the fate of the drug Avastin for breast cancer patients. In July of 2010, Avastin lost its right as a therapy to treat advanced, or metastatic, breast cancer when an advisory panel voted 12-1 to withdraw the drug. ... Only 20-25 percent of new breast cancer patients receive the drug, down from the former 60 percent before the panel voted (Hellerman). ... The drug was originally used for cancer of the lung, kidney, colon, and brain, but was granted provisional...
- Word Count: 1317
- Approx Pages: 5
- Has Bibliography
- Grade Level: Undergraduate